Tri­umvi­ra snags $55M Se­ries A to guide TAC tech­nol­o­gy to the clin­ic

Tri­umvi­ra Im­muno­log­ics wants to bring its T-cell anti­gen cou­pler (TAC) tech­nol­o­gy to the clin­ic ear­ly next year, and it plans on rid­ing a $55 mil­lion Se­ries A to get there.

The Austin, TX-based biotech an­nounced the com­ple­tion of its fi­nanc­ing round on Thurs­day. And now pres­i­dent and CEO Paul Lam­mers says it’s “all hands on deck” to sub­mit an IND for the com­pa­ny’s HER2-di­rect­ed TAC for sol­id tu­mor pa­tients. Lam­mers hopes the TAC will be ready for hu­man test­ing in late Q1 of 2021.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters